Britain and America have reached a significant trade agreement that will maintain no duties on British medicine products entering the US market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has committed to raise spending on medicines through the public health system. This pledge ensures that import taxes on these key exports will be held at zero for a duration of 36 months.
This development comes after previous threats to dramatically increase import taxes on patented pharmaceutical products, with increases mentioned reaching double the cost.
"This agreement with the UK bolsters the international landscape for new treatments and introduces long-overdue fairness to transatlantic pharmaceutical trade," a statement declared.
Trade Importance
Drugs constitute one of the Britain's biggest export categories to the United States, which is easily the biggest destination for leading companies like GSK and AstraZeneca.
Export figures indicate that in the 12 months leading up to last September, the UK shipped pharmaceutical products totaling £11.1bn to the US. This figure represented 17.4% of British export trade in that period.
"This deal protects jobs, boosts funding and sets the stage for the UK to emerge as a international leader for life sciences," the Business and Trade Secretary commented.
Specific UK Commitments
The deal entails several key pledges from the United Kingdom:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it judges new treatments to be unaffordable by 25%.
- Higher Drug Budget: There is a aim to increase total NHS spending on drugs from 0.3% of GDP to 0.6 percent over the next decade.
- Refund Ceiling: The amount drug companies must pay back to the NHS to stay within budget will be restricted at fifteen percent. Previously, refunds were more than twenty percent.
Broader Context
The deal takes place against a long-running tension between the pharmaceutical industry and the UK government over spending levels and approval rates.
The disagreement were intensified by claims that US consumers were charged a premium for the same drugs than people in the UK and Europe.
Recently, several significant drug company projects in the UK have been halted or scrapped, while major funding commitments have been pledged toward American operations.
A senior figure stated that the NHS had to invest a greater share on medicines, noting that its budget allocation on drugs had shrunk as a proportion of its resources over the past decade.
